AB0408 Comparative effectiveness of abatacept versus tnfi in patients with rheumatoid arthritis who are ccp+ in the united states corrona registry
Leslie R. Harrold(University of Massachusetts Chan Medical School), Joel M. Kremer(Research Foundation for the State University of New York), E. Alemao(Bristol-Myers Squibb (Sweden)), Seán Connolly(Bristol-Myers Squibb (Sweden)), Heather J. Litman(Thermo Fisher Scientific (United States)), Sabrina Rebello(Amyloidosis Foundation), Karen Price(Purchase College), S. Kelly(Bristol-Myers Squibb (Sweden)), Winnie Hua
Cited by 3
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183